Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

Overview of attention for article published in JACC, November 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

news: 5 news outlets
twitter: 52 X users
facebook: 2 Facebook pages

f1000: 1 research highlight platform
guideline: 2 clinical guideline sources

Readers on

mendeley: 253 Mendeley

So far, Altmetric has seen 65 X posts from 52 X users, with an upper bound of 511,114 followers.

@Rx_Ed Alirocumab does sir See plz this prespecified analysis from ODYSSEY OUTCOMES Trial https://t.co/yetDewxUSV

https://t.co/mPakugs2uP

RT @jpcostabel: Gran trabajo de @gabrielsteg 👏👏👏👏 https://t.co/EdQPbKjO0N https://t.co/lPz3fo4zsa

Gran trabajo de @gabrielsteg 👏👏👏👏 https://t.co/EdQPbKjO0N https://t.co/lPz3fo4zsa

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 61 additional X posts.